T cell therapies
Adaptimmune Terminates $3 Billion Collaboration with Roche’s Genentech for Off-the-Shelf T Cell Therapies
Adaptimmune, Roche, Genentech, Off-the-shelf T cell therapies, $3 billion biobucks pact, Collaboration termination
Actionable Insights Powered by AI
Adaptimmune, Roche, Genentech, Off-the-shelf T cell therapies, $3 billion biobucks pact, Collaboration termination